Biotech - Technical Analysis Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech - Technical Analysis

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jibacoa who wrote (108)	2/28/2002 3:15:47 PM
From: Jibacoa	Read Replies (1) of 544

ENMD Also had a good up-gap today.<g> Its Endostatin product received "Orphan Drug" approval from the FDA for treatment of melanoma (it had received same approval last August for treatment of neuroendocrine tumors)and they have scheduled a conference to release years end results on March 5. The net earnings for the Q ended Sept 30 were on black ink.<g> In January they reported a deal with Alergan. Resistance is now at the Jan.23-Feb.4 double top at the 8.50 level. siliconinvestor.com siliconinvestor.com Bernard

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next